BMO Capital Sticks to Their Buy Rating for 9 Meters Biopharma (NMTR)

BMO Capital analyst Gary Nachman maintained a Buy rating on 9 Meters Biopharma (NMTRResearch Report) today and set a price target of $5.00. The company’s shares closed last Thursday at $0.83, close to its 52-week low of $0.82.

According to, Nachman is ranked 0 out of 5 stars with an average return of -5.6% and a 39.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Pacira Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on 9 Meters Biopharma is a Strong Buy with an average price target of $5.00.

See today’s best-performing stocks on TipRanks >>

Based on 9 Meters Biopharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.54 million. In comparison, last year the company had a GAAP net loss of $8.33 million.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NMTR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Innovate Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It foucs on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

Read More on NMTR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More